Leadership Changes at Biote Corp.
Biote Corp. (NASDAQ: BTMD) has made significant announcements regarding its leadership, marking a pivotal moment for the company. Terry Weber, who has served as Chief Executive Officer, will retire from her role and step down from the Board of Directors, effective from the start of 2025. Alongside this transition, Bret Christensen has been appointed as the new CEO, also effective February 1, 2025.
Celebrating Terry Weber's Tenure
During her six years at Biote, Terry Weber has played an instrumental role in the company’s growth and influence in the health care sector. Under her guidance, Biote has emerged as a frontrunner in hormone optimization education, establishing a wide network of over 7,000 certified practitioners dedicated to enhancing patient health. Marc Beer, the Executive Chairman of the Board, expressed gratitude for Weber’s contributions, noting her fervent commitment to women's health and her strategic insights that positioned Biote for future success.
A Commitment to Health
Terry shared her reflections on leading Biote and emphasized the importance of advancing conversations in women's health. Her focus on addressing aging's medical challenges has not only benefitted countless individuals but has also advocated for improved practices within the health care sector.
Bret Christensen: A New Chapter Begins
Bret Christensen joins Biote with extensive experience in the health care industry, particularly in women's health. His previous roles at prominent companies, such as Hologic (NASDAQ: HOLX) and Myriad Genetics (NASDAQ: MYGN), highlight his capability to implement transformative health care solutions. He has a proven track record of driving successful product growth and establishing industry standards.
Vision for the Future
Mr. Christensen expressed excitement about his new role, stating that Biote is well-positioned to capitalize on its achievements in hormone optimization while expanding its therapeutic wellness initiatives. He envisions leveraging Biote’s advanced technology and practitioner training to offer high-impact health services and products that address the evolving needs of patients.
About Biote Corp.
Biote is transforming the landscape of healthy aging through its focus on personalized hormone optimization and wellness solutions provided by specially trained medical providers. By educating practitioners to spot early signs of aging and offering tailored treatments, Biote not only enhances patient well-being but also drives success for the clinics it partners with. The combination of personal care and professional training positions Biote as a leader in this underrepresented market.
Frequently Asked Questions
1. When is Terry Weber stepping down as CEO of Biote?
Terry Weber is set to retire as CEO and leave the Board of Directors on February 1, 2025.
2. Who is the new CEO of Biote Corp.?
Bret Christensen has been appointed the new CEO of Biote, also effective February 1, 2025.
3. What has Terry Weber accomplished during her tenure?
Terry Weber has significantly contributed to Biote’s growth and established a network of over 7,000 certified hormone optimization practitioners.
4. What is Bret Christensen's background?
Bret Christensen has over two decades of experience in health care, particularly in women’s health, with leadership roles at notable companies like Hologic and Myriad Genetics.
5. What is Biote’s focus in the health care sector?
Biote focuses on hormone optimization and therapeutic wellness, providing personalized solutions to enhance patient care and promote healthy aging.
